Drug-Related Side Effects and Adverse Reactions clinical trials

The registry lists 449 studies for Drug-Related Side Effects and Adverse Reactions across more than 10 countries. 77 are recruiting or about to start. 241 of them are mainly about Drug-Related Side Effects and Adverse Reactions (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 10 narrower conditions too, such as Cardiotoxicity: 1,116 studies, 249 open.

Get an email when these change. Save the Drug-Related Side Effects and Adverse Reactions studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 233
Status unknown: 84
Recruiting: 55
Active, not recruiting: 20
Not yet recruiting: 19
Terminated: 17

Phase

Phase 2: 57
Phase 1: 41
Phase 4: 36
Phase 3: 26

Where

United States: 140
China: 53
France: 35
Canada: 30
Spain: 16
United Kingdom: 14

Who runs them

University of British Columbia (7) · Brigham and Women's Hospital (7) · Assistance Publique - Hôpitaux de Paris (5) · Cipherome, Inc. (5) · VA Office of Research and Development (5) · Duke University (4) · Zhong Wang (4) · University Hospital, Montpellier (4)

Who develops what

Save this set

Every programme with a company-led study here in the last two years, whatever its size: 3 programmes from 3 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programmes — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

Dec 2026 est.GIPR Agonist LY3537021 · Eli Lilly and Company · Phase 2 named, not the main aimNCT07169851 A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer — primary endpoint: Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV · 204 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorised original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licences, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Drug-Related Side Effects and Adverse Reactions studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Nimotuzumab	1	0	2
Propofol	1	1	2
Ivermectin	1	0	1
Fexuprazan	1	0	1
Duloxetine	1	1	1
Furosemide	1	1	1
Vonoprazan	1	0	1
GIPR Agonist LY3537021	1	0	1
Remimazolam besilate	1	0	1
Remimazolam	1	0	1

Drug classes tested here Immune checkpoint inhibitors 2 open · Antimitotic agents 10 · Tyrosine kinase inhibitors (TKIs) 7 · Antimetabolites 7 · Alkylating agents 6

Coming up

3phase 3 studies under way

23studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jan 2027Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial) · Phase 3 · University of Texas Southwestern Medical Center
Jun 2027Melatonin for Prevention of Kidney Injury · Phase 3 · Rutgers, The State University of New Jersey
Nov 2026The Texas Interprofessional Pharmacogenomics (IPGx) · Texas A&M University
Dec 2026A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer · Eli Lilly and Company
Dec 2026Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic · Bjorn H. Ebdrup
Dec 2026NORTH-REG Dwell-Time Study · Jørgen Bjerggaard Jensen
Dec 2026A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors · Guangzhou FineImmune Biotechnology Co., LTD.
Dec 2026The Critical Care Recovery Program: Use of a Structured Clinic Visit to Reduce Adverse Drug Events in ICU Survivors · University of British Columbia
Dec 2026Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response · Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Dec 2026IMMUNO-FIT Observational Study · University Hospital Southampton NHS Foundation Trust

Who these studies take

Of the 55 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 37 (67%) set no upper age limit and 15 (27%) stop at 75 or younger. 14 (25%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 4 (7%) take healthy volunteers.

Recruiting studies that take each age, of 55
Age	Women	Men
10	12 (22%)	12 (22%)
18	48 (87%)	47 (85%)
30	44 (80%)	43 (78%)
40	44 (80%)	43 (78%)
50	44 (80%)	43 (78%)
65	47 (85%)	46 (84%)
75	46 (84%)	45 (82%)
85	40 (73%)	39 (71%)

Across all 449 studies, recruiting or not: 24% stop at 75 or younger and 16% at 65; 25% take children; 5% are for women only and 2% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Drug-Related Side Effects and Adverse Reactions studies take

Of 18 phase 4 interventional studies under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 4	19 mo17–37 · 18 studies	—	—
Interventional, no phase	26 mo12–43 · 73 studies	—	29 mo12–43 · 71 studies
Observational	45 mo24–97 · 69 studies	—	59 mo24–… · 65 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 16, 2026.

Results posted1

Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney InjuryNov 10, 2026NCT06264752

Newly registered2

Safety of Vonoprazan-Amoxicillin Dual Therapy Versus Concomitant Quadruple Therapy for H. Pylori EradicationNov 9, 2026NCT07924098
Efficacy and Safety of Oral Ivermectin for Genital WartsNov 3, 2026NCT07913321

Studies

Recruiting first, then most recently updated. Showing 50 of 449. Browse all 449 → or search them.